Table of Contents
Cannabis Use Linked to Higher Depressive Symptoms in Women, but Study Cannot Establish Cause
A large cross-sectional analysis of more than 20,000 U.S. adults from the National Health and Nutrition Examination Survey finds dose-dependent associations between cannabis use and depressive symptoms, with the strongest effects observed in women, but the study design fundamentally prevents any causal conclusions about the direction of the relationship.
Why This Matters
Cannabis is the most widely used federally illicit substance in the United States, and its consumption has been climbing steadily as state-level legalization expands. Depression is among the most prevalent and disabling psychiatric conditions worldwide. Whether regular cannabis use worsens depression, whether people with depression self-medicate with cannabis, or whether shared risk factors drive both remains one of the most consequential unanswered questions in behavioral health. Research that clarifies the nature, direction, and strength of this association, particularly across gender lines, has direct implications for screening, patient counseling, and public health policy.
Dealing with a condition like this?
Dr. Caplan has worked with 30,000+ patients on conditions like this. A consultation starts with your specific situation — not a generic protocol.
Book a consultation →Clinical Summary
Depression and cannabis use frequently co-occur, yet the nature of their relationship is poorly understood. This doctoral dissertation by A. Coughlin (Walden University, 2018) presents a cross-sectional secondary analysis of data from the National Health and Nutrition Examination Survey (NHANES) spanning 2005 to 2012. Using survey-weighted logistic regression on a sample of 20,150 adults aged 18 to 69, the author examined whether self-reported cannabis use frequency, quantity, and cessation history were associated with clinically significant depressive symptoms, defined as a score of 10 or higher on the Patient Health Questionnaire (PHQ-9). The study also explored secondary outcomes including antidepressant medication use and self-reported cardiovascular disease. The mechanistic rationale centers on endocannabinoid system dysregulation: chronic exogenous cannabinoid exposure may downregulate CB1 receptor signaling in mood-regulating circuits, potentially compounding depressive vulnerability, though this remains largely theoretical.
The principal finding was that women who were regular cannabis users had 1.8-fold higher odds of depressive symptoms compared to non-users or non-regular users (95% CI: 1.36 to 2.34), whereas the association in men was non-significant (OR = 1.05, 95% CI: 0.06 to 1.36). A dose-response pattern emerged, with use of six or more joints per day associated with more than double the odds of depressive symptoms (OR = 2.21, 95% CI: 1.07 to 4.2) relative to one joint per day, though wide confidence intervals limit precision. Cessation of cannabis use for one month or more was associated with 54% lower odds of depressive symptoms in women (OR = 0.46, 95% CI: 0.27 to 0.82). No significant association was detected between cannabis use and cardiovascular disease or antidepressant use, though the antidepressant analysis was severely underpowered. Critically, this is an unpublished dissertation that has not undergone peer review, and the cross-sectional design cannot establish temporal sequence or causation. The authors acknowledge that longitudinal research is needed before any clinical recommendations can be drawn.
Dr. Caplan’s Take
This study identifies a real and clinically recognizable pattern: women who use cannabis regularly do appear to carry a greater burden of depressive symptoms. That observation is consistent with what many of us see in practice. But I want to be very clear about the gap between this finding and the question patients most often ask, which is “Is cannabis making my depression worse?” This study simply cannot answer that question. Cross-sectional data capture a snapshot, not a trajectory. The association could run in either direction, or both could be driven by trauma, stress, socioeconomic factors, or other unmeasured variables. The fact that this is an unpublished dissertation, not a peer-reviewed publication, adds another layer of caution.
In my practice, when a patient with depression asks about cannabis, I discuss what we know and what we do not. I screen for cannabis use as part of a thorough intake, and I pay particular attention to dose escalation and functional impairment. If a patient is willing to trial a period of abstinence, I support that as a diagnostic and therapeutic experiment, not because one cross-sectional study told us cessation helps, but because removing a variable that may be complicating the clinical picture is sound medicine. What I do not do is cite this type of evidence as proof of harm.
Clinical Perspective
This analysis sits early in the research arc for this question. It is hypothesis-generating, not hypothesis-confirming. The gender-stratified finding in women is the most statistically robust result and aligns with a growing body of literature suggesting sex-based differences in both endocannabinoid system function and vulnerability to cannabis-related mood effects. However, the cross-sectional design means that reverse causation and confounding remain entirely plausible explanations. No causal pathway from cannabis to depression, or vice versa, can be inferred. The dose-response pattern is suggestive but imprecise, with overlapping confidence intervals across dose categories that raise questions about data stability. The cessation finding, while intriguing, is subject to the same temporal ambiguity: people who stop using cannabis may differ systematically from those who continue.
From a pharmacological standpoint, clinicians should be aware that cannabis can interact with commonly prescribed antidepressants, particularly SSRIs and SNRIs, through CYP450 enzyme inhibition, potentially altering drug metabolism. THC-dominant products carry well-established anxiogenic risk at higher doses, which may confound depressive symptom reporting. For clinicians working with this population now, the most actionable step is routine, non-judgmental screening for cannabis use in patients presenting with depressive symptoms, with particular attention to frequency, dose escalation, and gender-specific patterns. Document cannabis use as a clinical variable, track it longitudinally, and use structured instruments like the PHQ-9 to monitor symptom trajectories over time.
What Kind of Evidence Is This
This is an unpublished doctoral dissertation presenting an original cross-sectional analysis of nationally representative survey data. Cross-sectional studies sit relatively low in the evidence hierarchy because they capture associations at a single point in time and cannot establish temporal sequence or causation. The single most important inference constraint this design imposes is that it is impossible to determine whether cannabis use preceded depressive symptoms, whether depressive symptoms preceded cannabis use, or whether unmeasured third variables produced both. The absence of peer review adds an additional layer of uncertainty regarding methodological rigor.
How This Fits With the Broader Literature
The gender-stratified finding aligns with prior work suggesting that women may be more susceptible to cannabis-related mood effects, consistent with preclinical evidence of sex differences in endocannabinoid system signaling. A 2014 meta-analysis by Lev-Ran and colleagues, published in Psychological Medicine, similarly reported a modest association between cannabis use and depression, though heterogeneity across included studies was substantial. The present analysis extends prior work by examining dose-response and cessation patterns in a large nationally representative sample, but it does not resolve the central ambiguity that has plagued this literature for decades: directionality.
The null finding for cardiovascular disease is consistent with the mixed and inconclusive state of that evidence base, while the antidepressant analysis is too underpowered to contribute meaningfully. Longitudinal cohort studies and, ideally, randomized designs examining cannabis cessation effects on mood trajectories remain the critical next step that the field requires.
Common Misreadings
The most likely overinterpretation is concluding that cannabis causes depression in women. The 1.8-fold odds ratio is an association observed at a single time point, not evidence of a causal pathway. People with depression may be more likely to use cannabis as a coping mechanism, or shared factors such as childhood adversity, chronic pain, or socioeconomic stress may independently elevate both cannabis use and depressive symptoms. Similarly, the cessation finding should not be read as evidence that quitting cannabis reduces depression; individuals who successfully stop using cannabis may differ from those who continue in ways the study did not measure, including motivation, social support, and baseline symptom severity.
Bottom Line
This large, nationally representative cross-sectional analysis identifies a statistically significant association between regular cannabis use and depressive symptoms in women, with a suggestive dose-response pattern. However, the study design cannot determine whether cannabis contributes to depression, whether depression drives cannabis use, or whether both reflect shared vulnerabilities. As an unpublished dissertation lacking peer review, these findings are best treated as hypothesis-generating. They reinforce the importance of routine cannabis screening in patients with depressive symptoms but do not support definitive clinical claims about causation or treatment.
Frequently Asked Questions
Does this study prove that cannabis causes depression?
No. This study used a cross-sectional design, which means it looked at cannabis use and depressive symptoms at the same point in time. It found that the two tend to occur together in women, but it cannot tell us which came first or whether something else entirely is responsible for both. Proving causation would require a different type of study that follows people over time or uses experimental methods.
Why was the association stronger in women than in men?
The study found a statistically significant association in women but not in men, though it did not definitively explain why. Possible explanations include biological sex differences in how the endocannabinoid system processes THC, differences in patterns and motivations for cannabis use, and differences in baseline depression rates between genders. This is an active area of research and no single explanation has been established.
Should women who use cannabis for anxiety or mood issues stop based on this study?
This study alone is not sufficient basis for a blanket recommendation to
